

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **VOLUNTARY ANNOUNCEMENT**

## **BIOCYTOGEN ENTERS INTO ANTIBODY AGREEMENT WITH ONA THERAPEUTICS TO DEVELOP ANTIBODY-DRUG CONJUGATES TARGETING SOLID TUMORS**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**” or “**Biocytogen**”, together with its subsidiaries, the “**Group**”) is pleased to announce an antibody evaluation, option and license agreement (the “**Agreement**”) with Ona Therapeutics (“**Ona**”), a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.

Under the terms of the Agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice<sup>®</sup>-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for antibody-drug conjugate (the “**ADC**”) development, manufacturing and commercialization in mutually agreed indications and territories.

Biocytogen will receive an upfront payment for granting the option, and will be further entitled to an option-exercise fee, development and commercialization milestone payments, as well as single-digit royalties on net sales once Ona elects to exercise the option in full.

Dr. Yuelei Shen, the chairman of the Board, chief executive officer and executive Director of the Company, said: “As part of Project Integrum, Biocytogen has been discovering fully human antibodies against more than 200 tumor-associated antigens (TAA) targets based on their internalization activity. We are honored that Ona, among other global biopharmaceutical companies, recognizes the potential of our proprietary off-the-shelf antibodies. We believe Ona’s deep understanding of novel mechanisms of resistance in advanced cancer and their capabilities in ADC design and development will accelerate the development of our antibodies into promising therapeutics.”

Dr. Valerie Vanhooren, chief executive officer & co-founder of Ona, said: “We look forward to evaluating Biocytogen’s proprietary antibodies for ADC uses. We believe the combination of Biocytogen’s rich antibody repertoire with Ona’s unique insight in advanced cancer biology will have great advantages in the discovering and developing of first-in-class molecules for unmet medical needs.”

To the best knowledge and belief of the Directors, as of the date of this announcement, Ona is independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

**This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**  
**Shen Yuelei**

*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, December 18, 2023

*As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*

## **Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors**

Beijing, China and Barcelona, Spain, December 18, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“**Biocytogen**” or “**Company**”) (Stock Code: 02315.HK), a global biotech company focusing on the discovery and development of novel antibody therapeutics, announces an antibody evaluation, option and license agreement (the “**Agreement**”) with Ona Therapeutics (“**Ona**”), a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.

Under the terms of the Agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice<sup>®</sup>-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for antibody-drug conjugate (the “**ADC**”) development, manufacturing and commercialization in mutually agreed indications and territories.

Biocytogen will receive an upfront payment for granting the option, and will be further entitled to an option-exercise fee, development and commercialization milestone payments, as well as single-digit royalties on net sales once Ona elects to exercise the option in full.

Dr. Yuelei Shen, the chairman of the Board, chief executive officer and executive Director of the Company, said: “As part of Project Integrum, Biocytogen has been discovering fully human antibodies against more than 200 tumor-associated antigens (TAA) targets based on their internalization activity. We are honored that Ona, among other global biopharmaceutical companies, recognizes the potential of our proprietary off-the-shelf antibodies. We believe Ona’s deep understanding of novel mechanisms of resistance in advanced cancer and their capabilities in ADC design and development will accelerate the development of our antibodies into promising therapeutics.”

Dr. Valerie Vanhooren, chief executive officer & co-founder of Ona, said: “We look forward to evaluating Biocytogen’s proprietary antibodies for ADC uses. We believe the combination of Biocytogen’s rich antibody repertoire with Ona’s unique insight in advanced cancer biology will have great advantages in the discovering and developing of first-in-class molecules for unmet medical needs.”

### **About Biocytogen**

Biocytogen (Stock Code: 02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice<sup>®</sup> (RenMab<sup>™</sup>/RenLite<sup>®</sup>/RenNano<sup>®</sup>/RenTCR-mimic<sup>™</sup>) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established an off-the-shelf library of >400,000 fully human antibody sequences for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice<sup>®</sup> licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (the “**MNCs**”). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice<sup>™</sup>, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).

For more information, please visit the Company's website at <http://en.biocytogen.com.cn>.

### **About Ona Therapeutics**

Ona, headquartered in the Barcelona Science Park (PCB), Barcelona, Spain, is a biotech company that specializes in unravelling novel biology to design first-in-class biopharmaceuticals attacking advanced cancer. The company was founded in 2019 as a spin-off from ICREA and the IRB Institute for Research in Biomedicine. In 2020, Ona raised a EUR 30 million Series A investment round from an international syndicate of life sciences specialist investors. Ona was named by Fierce Biotech as one of 2020's Fierce 15 biotechnology companies.

For more information please visit Ona's website at [www.ona-therapeutics.com](http://www.ona-therapeutics.com).

### **Forward-Looking Statements**

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of the directors or the Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.